Drug Profile


Alternative Names: Apleway; CSG452; Deberza; R 7201; RG 7201; RO4998452; Tofogliflozin hydrate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Kowa; Osaka University School of Medicine; Sanofi K.K.
  • Class Antihyperglycaemics; Benzhydryl compounds; Benzofurans; Glucosides; Small molecules; Spiro compounds
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Atherosclerosis

Most Recent Events

  • 01 Mar 2017 Phase-II clinical trials in Type-2 diabetes mellitus (Adjunctive treatment, Treatment-experienced) in Japan (PO) (UMIN000026161)
  • 03 Jan 2017 Phase-II clinical trials in Type-2 diabetes mellitus in European Union, USA (PO)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top